- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05731882
First in Man Study of Left Atrial Appendage Pulsed Field Ablation Occluder
January 16, 2024 updated by: Hangzhou Dinova EP Technology Co., Ltd
First in Man Study to Evaluate Safety and Efficacy of Left Atrial Appendage Pulsed Field Ablation Occluder for Simultaneous Pulsed Field Ablation and Mechanical Closure of the Left Atrial Appendage in Patients With Nonvalvular Atrial Fibrillation
This is the first in man study of E-SeaLATM developed and manufactured by Hangzhou Dinova EP Technology Co., Ltd, which can achieve pulsed field ablation and mechanical closure of the Left Atrial Appendage simultaneously, this study aims to initially verify the safety and efficacy of the device.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Min Tang, professor
- Phone Number: +86037158680341
- Email: dinova_ep@dnaeps.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Fuwai Hospital, Chinese Academy of Medical Sciences
-
Contact:
- Min Tang, professor
- Email: dinova_ep@dnamedtech.com
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- Fuwai Central China Cardiovascular Hospital
-
Contact:
- Xianqing Wang, professor
-
-
Liaoning
-
Shenyang, Liaoning, China, 110016
- Recruiting
- General Hospital of Northern Theater Command
-
Contact:
- Zulu Wang, professor
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- The age of the patient is 18~80 years old;
- patients diagnosed with non-valvular atrial fibrillation (at least 1 episode of atrial fibrillation recorded on ECG or Holter in the 12 months prior to enrollment);
- CHA2DS2-VASC score: male≥ 2, female≥ 3;
- patients are not suitable for long-term oral anticoagulant therapy (any of the following): (1) not suitable for long-term standardized anticoagulation therapy; (2) stroke or embolism still occurs on the basis of long-term standardized anticoagulation therapy; (3) HAS-BLED score≥ 3 points; (4) need to be treated with antiplatelet drugs; (5) unwillingness to undergo long-term anticoagulant therapy;
- Be able to understand the purpose of the study, voluntarily participate in the study, sign the informed consent form by the subject himself or her legal representative, and be willing to complete the follow-up in accordance with the requirements of the program.
Exclusion Criteria:
- Atrial fibrillation secondary to electrolyte imbalances, thyroid disease or other reversible factors;
- Left atrial appendage depth < 15mm, left atrial appendage anchor area < 10mm or >33mm;
- Left atrial diameter≥ 65mm;
- Imaging examination shows left atrium or left atrial appendage thrombosis;
- Severe structural heart disease (such as moderate to severe aortic valve, mitral stenosis or regurgitation);
- Left ventricular ejection fraction <35%, or New York College of Cardiology class III or IV;
- Refractory hypertension (blood pressure persists > 180/110mmHg after treatment);
- Patients with previous patent foramen ovale closure, atrial septal defect closure or repair;
- Patients with previous left atrial appendage occlusion or left atrial appendage closure;
- Patients with previous valve repair, prosthetic valve implantation or replacement;
- Patients who have implanted devices such as implantable cardioverter defibrillator(ICD), cardiac resynchronization therapy(CRT) or pacemaker or have an implantation plan within 12 months after procedure;
- Patients with clinically symptomatic carotid artery stenosis, or patients who have undergone carotid stenting or carotid endarterectomy in the past 6 months;
- Patients with a history of myocardial infarction in the past 6 months, or who have undergone coronary artery bypass grafting or percutaneous coronary intervention;
- Recorded thromboembolic events (including transient ischemic attack) in the past 30 days;
- Serum creatinine greater than 2 times the upper limit of normal, or history of renal dialysis;
- Acute systemic infection;
- Severe lung disease, pulmonary hypertension or any lung disease involving abnormal blood gases or severe breathing difficulties;
- Presence of wall thrombosis, tumors or other abnormalities that interfere with vascular puncture or catheter operation;
- Female patients who are pregnant, lactating, or unable to use contraception during the study;
- patients have participated in clinical trials of other drugs or devices during the same period;
- patient's life expectancy is less than 12 months;
- Abnormalities or diseases that the investigator believes should be excluded from the scope of enrollment in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Catheter ablation+E-SeaLATM
|
First, pulmonary vein isolation(PVI) was performed with the novel hex spline PFA ablation catheter( CardioPulseTM PFA system, Hangzhou Dinova EP Technology Co., Ltd), then, pulsed field ablation and mechanical closure of the left atrial appendage were achieved by E-SeaLATM(Hangzhou Dinova EP Technology Co., Ltd) implantation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success rate
Time Frame: immediately after the procedure
|
Technical success means that the pulmonary vein and left atrial appendage(LAA) remain electrical isolation 20 minutes after ablation, and the per-device leaks≤ 3 mm after E-SeaLA LAA pulsed field ablation(PFA) occluder implantation.
|
immediately after the procedure
|
The incidence of major adverse events (MAEs) related to devices or procedures 3 months after procedure
Time Frame: within 3 months after procedure
|
MAE includes death, myocardial infarction, stroke or transient ischemic attack (TIA), pulmonary vein stenosis, phrenic nerve palsy, systemic embolism, pericarditis, pericardial effusion/cardiac tamponade, atrial esophageal fistula, severe vascular access complications, device migration, and device embolization.
|
within 3 months after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ablation efficiency including total procedure time, catheter dwell time, total ablation time and total X-ray exposure time
Time Frame: immediately after the procedure
|
Total procedure time (defined as the total time from initial femoral venipuncture to final catheter removal), catheter dwell time (time between the pulsed field ablation catheter entering the left atrium and its withdrawal from the left atrium), total ablation time (including total PVI ablation time, total LAA ablation time), total X-ray exposure time (the total time of X-ray imaging of the catheter).
|
immediately after the procedure
|
Left atrial appendage closure rate 12 months after procedure
Time Frame: within 12 months after procedure
|
after occlusion device implantation, no forward or reverse blood flow through the occluder confirmed by ultrasound, residual forward or reverse blood flow at the edge of the occluder ≤3mm, peri-device leaks ≥grade 3)
|
within 12 months after procedure
|
Incidence of ischemic stroke within 12 months after procedure (event/patient-year).
Time Frame: within 12 months after procedure
|
Ischemic stroke refers to the loss of neurological function caused by transient ischemic attack, cerebral thrombosis or cerebral embolism caused by the lesions of the brain itself and/or systemic blood circulation disorders leading to cerebral blood supply disorders.
Ischemic stroke is defined as a modified Rankin score (mRS) ≥2 90 days after stroke onset.
|
within 12 months after procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 17, 2022
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
August 1, 2024
Study Registration Dates
First Submitted
January 30, 2023
First Submitted That Met QC Criteria
February 7, 2023
First Posted (Actual)
February 16, 2023
Study Record Updates
Last Update Posted (Actual)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 16, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- E-SeaLA FIM 01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonvalvular Atrial Fibrillation
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingNonvalvular Atrial FibrillationChina
-
Gérond'ifRecruitingNonvalvular Atrial FibrillationFrance
-
Bristol-Myers SquibbCompletedNonvalvular Atrial Fibrillation
-
University Hospital, AngersBayerRecruiting
-
Baim Institute for Clinical ResearchAmerican College of CardiologyCompletedNonvalvular Atrial FibrillationUnited States
-
Bristol-Myers SquibbPfizerCompletedNonValvular Atrial FibrillationJapan
-
AstraZenecaCompletedNonvalvular Atrial Fibrillation
-
NovartisCompletedPersistent Nonvalvular Atrial FibrillationUnited States, Germany
-
BayerJanssen Research & Development, LLCCompletedNonvalvular Atrial FibrillationUnited States
-
Bristol-Myers SquibbCompleted
Clinical Trials on E-SeaLA, CardioPulse PFA system
-
Galaxy Medical, Inc.Active, not recruitingAtrial FibrillationCanada
-
Medtronic Cardiac Rhythm and Heart FailureCompletedAtrial FibrillationUnited States, Canada, Spain, Japan, Netherlands, Belgium, Australia, Austria, France
-
Bartın UnıversityRecruitingAnxiety | Pain, Acute | Child, OnlyTurkey
-
Hangzhou Dinova EP Technology Co., LtdActive, not recruitingAtrial FibrillationChina
-
Massachusetts Institute of TechnologyIntegrum; Brigham and Women's HospitalRecruiting
-
Medical University of South CarolinaCompleted
-
The University of Hong KongTuen Mun Hospital; Lingnan UniversityUnknownHealth Knowledge, Attitudes, PracticeHong Kong
-
IntegrumBrigham and Women's Hospital; Massachusetts Institute of TechnologyActive, not recruiting
-
JOTEC GmbHCompletedIliac AneurysmGermany, Spain, Poland, Austria
-
The National Center on Addiction and Substance...National Institute on Drug Abuse (NIDA)Recruiting